Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FF EAI Robotics Ecosystem Inc.QLGN · Entity 7776 | Director | July 11, 2022 | August 04, 2022 |
| LIFECORE BIOMEDICAL, INC. \DE\LFCR · Entity 6447 | Director | June 04, 2026 | June 05, 2026 |
| LIGAND PHARMACEUTICALS INCLGND · Entity 3825 | President & COO | September 20, 2024 | September 24, 2024 |
| PALVELLA THERAPEUTICS, INC.PVLA · Entity 4452 | CFO, Treasurer | June 12, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FF EAI Robotics Ecosystem Inc.
Report date July 11, 2022 · Filed August 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.51 · Expires 2032-07-11 | Direct | 40,000 |
Reported balance
After 2022-07-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-07-11 · Grant · Acquired 40,000 · Balance 40,000 F1: Shares underlying the stock option vest over three years in equal annual installments from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares underlying the stock option vest over three years in equal annual installments from the date of grant.
LIFECORE BIOMEDICAL, INC. \DE\
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 69,967 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 25,907 · Balance 69,967 F1: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2: Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026). |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
F2: Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).
LIGAND PHARMACEUTICALS INC
Report date September 20, 2024 · Filed September 24, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 50,777 |
Ending reported balance
After 2024-09-23 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2024-09-20 · Exercise / conversion · Acquired 4,982 · Balance 57,052 Row 2 · 2024-09-20 · Sale · Disposed 6,275 · Balance 50,777 F1: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $104.0000 to $104.4300. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2024-09-23 · Exercise / conversion · Acquired 395 · Balance 51,172 Row 4 · 2024-09-23 · Exercise / conversion · Acquired 9,377 · Balance 60,549 Row 5 · 2024-09-23 · Sale · Disposed 2,481 · Balance 58,068 F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $100.0000 to $100.2750. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 6 · 2024-09-23 · Sale · Disposed 7,090 · Balance 50,978 F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $101.0450 to $102.0400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 7 · 2024-09-23 · Sale · Disposed 201 · Balance 50,777 F4: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $102.0450 to $102.0950. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.99 · Expires 2026-02-11 | Direct | 395 |
Reported balance
After 2024-09-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-09-20 · Exercise / conversion · Disposed 4,982 · Balance 395 F5: This Option was previously reported as a Grant of 18,464 shares on February 11, 2016, which vested in full on February 11, 2020, at an exercise price of $85.79 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.99 · Expires 2026-02-11 | Direct | 0 |
Reported balance
After 2024-09-23 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-09-23 · Exercise / conversion · Disposed 395 · Balance 0 F5: This Option was previously reported as a Grant of 18,464 shares on February 11, 2016, which vested in full on February 11, 2020, at an exercise price of $85.79 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.84 · Expires 2032-05-05 | Direct | 42,436 |
Reported balance
After 2024-09-23 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2024-09-23 · Exercise / conversion · Disposed 9,377 · Balance 42,436 F6: This Option was previously reported as a Grant of 30,189 shares on May 5, 2022, at an exercise price of $90.68 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer and shall be fully vested on February 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $104.0000 to $104.4300. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $100.0000 to $100.2750. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $101.0450 to $102.0400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $102.0450 to $102.0950. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: This Option was previously reported as a Grant of 18,464 shares on February 11, 2016, which vested in full on February 11, 2020, at an exercise price of $85.79 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.
F6: This Option was previously reported as a Grant of 30,189 shares on May 5, 2022, at an exercise price of $90.68 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer and shall be fully vested on February 5, 2026.
PALVELLA THERAPEUTICS, INC.
Report date June 12, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,000 |
Reported balance
After 2026-06-12 transaction · row 1
1 source rowRow 1 · 2026-06-12 · Exercise / conversion · Acquired 1,000 · Balance 1,000 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.60 · Expires 2034-12-13 | Direct | 166,100 |
Reported balance
After 2026-06-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-12 · Exercise / conversion · Disposed 1,000 · Balance 166,100 F1: 25% of the stock options will vest on October 16, 2025, and the remaining 75% will vest in equal monthly tranches over the following 36 months. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the stock options will vest on October 16, 2025, and the remaining 75% will vest in equal monthly tranches over the following 36 months.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 28, 2022 Filed Dec 30, 2022 22:00 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 3,859 | $66.29 | $255,813.11 |
DisclosureSEC source: 0000899243-22-039583 · doc4.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,569 Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 23:34 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantEmployee Stock Option (right to buy) · Derivative | 25,967 | $0.00 Strike: $67.03 | $0.00 |
DisclosureSEC source: 0000899243-22-039412 · doc4.xml · derivative · entry 1 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,967 Underlying: Common Stock · 25,967 shares Expires 2032-12-22 F1 · derivative.exercise_date: Grant to reporting person of stock options that will vest and become exercisable over a 4-year period measured from the date of grant, with 12-1/2% of the shares subject to the stock options vesting on the date that is six months after the date of grant and the remaining stock options vesting in 42 equal monthly installments thereafter. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 23:17 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantEmployee Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $63.62 | $0.00 |
DisclosureSEC source: 0000899243-22-038699 · doc4.xml · derivative · entry 2 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-12-13 F2 · derivative.exercise_date: Grant to reporting person of stock options that will vest and become exercisable over a 4-year period measured from December 5, 2022, with 12-1/2% of the shares subject to the stock options vesting on the date that is six months after December 5, 2022 and the remaining stock options vesting in 42 equal monthly installments thereafter. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 23:17 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-038699 · doc4.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,428 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three equal annual installments on December 5, 2023; December 5, 2024; and December 5, 2025, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| November 30, 2022 Filed Dec 2, 2022 02:42 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 3,593 | $72.90 | $261,929.70 |
DisclosureSEC source: 0000899243-22-037330 · doc4.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,428 Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:10 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 27,714 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-035047 · doc4.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,021 F1 · shares: Includes 19,258 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire. F2 · balance_after: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the OmniAb, Inc. from the Issuer on November 1, 2022. Read SEC document |
| July 11, 2022 Filed Aug 4, 2022 20:16 UTC | FF EAI Robotics Ecosystem Inc. QLGN · Entity 7776 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001493152-22-021319 · ownership.xml · derivative · entry 1 Korenberg Matthew E · CIK 0001649903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-07-11 F1 · derivative.exercise_date: Shares underlying the stock option vest over three years in equal annual installments from the date of grant. Read SEC document |
| June 30, 2022 Filed Jul 7, 2022 00:00 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | OtherCommon Stock | 164 | $75.84 | $12,437.27 |
DisclosureSEC source: 0000886163-22-000107 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,532 F1 · kind: Shares acquired under Ligand's employee stock purchase plan. Voluntary reporting exemption under Rule 16b-3(c). Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 21:54 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 8,062 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-22-000090 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,368 Read SEC document |
| May 05, 2022 Filed May 10, 2022 00:10 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantEmployee Stock Option (right to buy) · Derivative | 30,189 | $0.00 Strike: $90.68 | $0.00 |
DisclosureSEC source: 0000886163-22-000056 · edgardoc.xml · derivative · entry 1 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,189 Underlying: Common Stock · 30,189 shares Expires 2032-05-05 F1 · derivative.exercise_date: Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exerciseable over a 3-year, 9-month period measured from the date of grant, 12-1/2% after three months, then 1/48th of the Option Shares per month thereafter. The date of grant is 05/05/2022. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 01:23 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,532 | $123.68 | $189,477.76 |
DisclosureSEC source: 0000886163-22-000021 · edgardoc.xml · nonDerivative · entry 3 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,306 F3 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/03/2021. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 01:23 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 969 | $123.68 | $119,845.92 |
DisclosureSEC source: 0000886163-22-000021 · edgardoc.xml · nonDerivative · entry 2 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,838 F2 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/13/2020. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 01:23 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 906 | $123.68 | $112,054.08 |
DisclosureSEC source: 0000886163-22-000021 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,807 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/11/2019. Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 01:43 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 2,309 | $113.68 | $262,487.12 |
DisclosureSEC source: 0000886163-22-000014 · edgardoc.xml · nonDerivative · entry 4 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,713 F3 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 01:43 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,319 | $113.68 | $149,943.92 |
DisclosureSEC source: 0000886163-22-000014 · edgardoc.xml · nonDerivative · entry 3 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,022 F3 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 01:43 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 6,848 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-22-000014 · edgardoc.xml · nonDerivative · entry 2 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,341 F2 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 03/09/2020 and were eligible to vest based on the Issuer achievement of certain performance objectives during the two-year performance period ending December 31, 2021. On January 26, 2022, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 01:43 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 4,803 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-22-000014 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,493 F1 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 05/29/2019 and were eligible to vest based on the Issuer achievement of certain performance objectives during the three-year performance period ending December 31, 2021. On January 26, 2022, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 21:13 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | OtherCommon Stock | 247 | $85.91 | $21,219.65 |
DisclosureSEC source: 0000886163-21-000097 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,690 F1 · kind: Shares acquired under Ligand's employee stock purchase plan. Voluntary reporting exemption under Rule 16b-3(c). Read SEC document |
| February 15, 2021 Filed Feb 18, 2021 23:27 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 969 | $172.46 | $167,113.74 |
DisclosureSEC source: 0000886163-21-000040 · edgardoc.xml · nonDerivative · entry 3 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,443 F3 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/13/2020. Read SEC document |
| February 15, 2021 Filed Feb 18, 2021 23:27 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 906 | $172.46 | $156,248.76 |
DisclosureSEC source: 0000886163-21-000040 · edgardoc.xml · nonDerivative · entry 2 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,412 F2 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/11/2019. Read SEC document |
| February 15, 2021 Filed Feb 18, 2021 23:27 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 434 | $172.46 | $74,847.64 |
DisclosureSEC source: 0000886163-21-000040 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,318 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 03/02/2018. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 22:02 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantEmployee Stock Option (right to buy) · Derivative | 11,591 | $0.00 Strike: $177.50 | $0.00 |
DisclosureSEC source: 0000886163-21-000027 · edgardoc.xml · derivative · entry 2 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,591 Underlying: Common Stock · 11,591 shares Expires 2031-02-03 F1 · derivative.exercise_date: Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exerciseable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/03/2021. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 22:02 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 10,819 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-21-000027 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,752 Read SEC document |
| January 25, 2021 Filed Jan 28, 2021 00:03 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,440 | $156.01 | $224,654.40 |
DisclosureSEC source: 0000886163-21-000014 · edgardoc.xml · nonDerivative · entry 4 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,933 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document |
| January 25, 2021 Filed Jan 28, 2021 00:03 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 4,803 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-21-000014 · edgardoc.xml · nonDerivative · entry 3 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,373 F3 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 05/29/2019 and were eligible to vest based on the Issuer achievement of certain performance objectives during the two-year performance period ending December 31, 2020. On January 25, 2021, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document |
| January 25, 2021 Filed Jan 28, 2021 00:03 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 671 | $156.01 | $104,682.71 |
DisclosureSEC source: 0000886163-21-000014 · edgardoc.xml · nonDerivative · entry 2 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,570 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document |
| January 25, 2021 Filed Jan 28, 2021 00:03 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 2,305 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-21-000014 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,241 F1 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 05/30/2018 and were eligible to vest based on the Issuer achievement of certain performance objectives during the three-year performance period ending December 31, 2020. On January 25, 2021, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 00:05 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | OtherCommon Stock | 238 | $89.03 | $21,188.90 |
DisclosureSEC source: 0000886163-20-000083 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,936 F1 · kind: Shares acquired under Ligand's employee stock purchase plan. Voluntary reporting exemption under Rule 16b-3(c). Read SEC document |
| June 06, 2020 Filed Jun 9, 2020 01:22 UTC | FF EAI Robotics Ecosystem Inc. QLGN · Entity 7776 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001493152-20-010817 · ownership.xml · derivative · entry 1 Korenberg Matthew E · CIK 0001649903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-06-06 F1 · derivative.exercise_date: Shares underlying the stock option vest over three years in equal annual installments from the date of grant. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 22:05 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantEmployee Stock Option (right to buy) · Derivative | 30,750 | $0.00 Strike: $95.68 | $0.00 |
DisclosureSEC source: 0000886163-20-000014 · edgardoc.xml · derivative · entry 2 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,750 Underlying: Common Stock · 30,750 shares Expires 2030-02-13 F1 · derivative.exercise_date: Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exerciseable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/13/2020. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 22:05 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 6,848 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-20-000014 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,864 Read SEC document |
| December 20, 2019 Filed Dec 26, 2019 19:01 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 979 | $105.87 | $103,646.73 |
DisclosureSEC source: 0000886163-19-000209 · edgardoc.xml · nonDerivative · entry 4 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,016 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document |
| December 20, 2019 Filed Dec 26, 2019 19:01 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 2,305 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-19-000209 · edgardoc.xml · nonDerivative · entry 3 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,995 F3 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 05/30/2018 and were eligible to vest based on the Issuer achievement of certain performance objectives during the two-year performance period ending December 31, 2019. On December 20, 2019, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document |
| December 20, 2019 Filed Dec 26, 2019 19:01 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,135 | $105.87 | $120,162.45 |
DisclosureSEC source: 0000886163-19-000209 · edgardoc.xml · nonDerivative · entry 2 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,690 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document |
| December 20, 2019 Filed Dec 26, 2019 19:01 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 2,674 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-19-000209 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,825 F1 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 03/29/2017 and were eligible to vest based on the Issuer achievement of certain performance objectives during the three-year performance period ending December 31, 2019. On December 20, 2019, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document |
| September 19, 2019 Filed Sep 23, 2019 14:14 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Purchase0.75% Convertible Senior Notes due 2023 · Derivative | Not disclosed | $989,937.50 Strike: $248.48 | $1,175,000.00 |
DisclosureSEC source: 0000886163-19-000175 · edgardoc.xml · derivative · entry 1 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · Not disclosed shares Expires 2023-05-15 F1 · derivative.exercise_date: The notes are convertible at any time prior to the close of business on November 14, 2022 (1) during any fiscal quarter (and only during such fiscal quarter) commencing after September 30, 2018, if, for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of the Issuer?s common stock on such trading day is greater than 130% of the conversion price on such trading day; (2) during the five business day period immediately following any 10 consecutive trading day period, in which the trading price per $1,000 principal amount of notes was less than 98% of the product of the last reported sale price of our common stock on such trading day and the conversion rate on each such trading day; or (3) upon the occurrence of certain specified corporate events as specified in the indenture governing the notes. Read SEC document |
| September 03, 2019 Filed Sep 3, 2019 23:34 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | PurchaseCommon Stock | 500 | $86.18 | $43,090.75 |
DisclosureSEC source: 0000886163-19-000161 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,151 Read SEC document |
| June 28, 2019 Filed Jul 3, 2019 01:49 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | OtherCommon Stock | 182 | $97.03 | $17,659.01 |
DisclosureSEC source: 0000886163-19-000120 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,651 F1 · kind: Shares acquired under Ligand's employee stock purchase plan. Voluntary reporting exemption under Rule 16b-3(c). Read SEC document |
| February 15, 2019 Filed Apr 24, 2020 23:24 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 435 | $120.86 | $52,574.10 |
DisclosureSEC source: 0000886163-20-000052 · edgardoc.xml · nonDerivative · entry 3 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,303 F3 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 03/02/2018. Read SEC document |
| February 15, 2019 Filed Apr 24, 2020 23:24 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 377 | $120.86 | $45,564.22 |
DisclosureSEC source: 0000886163-20-000052 · edgardoc.xml · nonDerivative · entry 2 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,738 F2 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/24/2017. Read SEC document |
| February 15, 2019 Filed Apr 24, 2020 23:24 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 354 | $120.86 | $42,784.44 |
DisclosureSEC source: 0000886163-20-000052 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,115 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/11/2016. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 21:35 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantEmployee Stock Option (right to buy) · Derivative | 29,298 | $0.00 Strike: $117.97 | $0.00 |
DisclosureSEC source: 0000886163-19-000037 · edgardoc.xml · derivative · entry 2 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,298 Underlying: Common Stock · 29,298 shares Expires 2029-03-02 F1 · derivative.exercise_date: Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exerciseable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/11/19. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 21:35 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 6,404 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-19-000037 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,469 Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 21:30 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 612 | $111.78 | $68,409.36 |
DisclosureSEC source: 0000886163-19-000016 · edgardoc.xml · nonDerivative · entry 4 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,065 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 21:30 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 2,230 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-19-000016 · edgardoc.xml · nonDerivative · entry 3 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,677 F3 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 03/29/2017 and were eligible to vest based on the Issuer achievement of certain performance objectives during the two-year performance period ending December 31, 2018. On January 23, 2019, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 21:30 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 713 | $111.78 | $79,699.14 |
DisclosureSEC source: 0000886163-19-000016 · edgardoc.xml · nonDerivative · entry 2 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,447 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 21:30 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 2,418 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-19-000016 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,160 F1 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 02/11/2016 and were eligible to vest based on the Issuer achievement of certain performance objectives during the three-year performance period ending December 31, 2018. On January 23, 2019, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document |
| August 29, 2018 Filed Aug 30, 2018 00:35 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 11,540 | $0.00 Strike: $85.79 | $0.00 |
DisclosureSEC source: 0000886163-18-000125 · edgardoc.xml · derivative · entry 3 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,924 Underlying: Common Stock · 11,540 shares Expires 2026-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/11/16. Read SEC document |
| August 29, 2018 Filed Aug 30, 2018 00:35 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 18,357 | $256.69 | $4,712,060.17 |
DisclosureSEC source: 0000886163-18-000125 · edgardoc.xml · nonDerivative · entry 2 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,742 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $256.218 to $257.170, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 29, 2018 Filed Aug 30, 2018 00:35 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 11,540 | $85.79 | $990,016.60 |
DisclosureSEC source: 0000886163-18-000125 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.